Talking Ketamine Podcast

Talking Ketamine
  • 4.3 (12)
  • Mental Health
  • Updated Weekly

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. Each episode explores a recent scientific study that explores an interesting aspect of ketamine treatment, ketamine therapy, and ketamine use in mental health. The podcast has covered topics ranging from ketamine and music to ketamine's surprising help in battling some cancers. Most of the papers covered are cutting edge science so you may not want to make medical decisions from them. But, each piece of evidence, good or bad, big or small, guides us to a better understanding of this miraculous medicine. If you are interested in ketamine research because you suffer from MDD or are having thoughts of suicide, please dial 988 or visit https://988lifeline.org in the US or go to https://findahelpline.com/ to find help in your location.

  1. Couples Therapy on Ketamine

    5d ago

    Couples Therapy on Ketamine

    For many couples, traditional talk therapy can feel like an endless loop, failing to break through entrenched patterns of distress. The stark reality? Up to a third of couples find conventional therapy ineffective, often relapsing into old arguments because logic crumbles when the nervous system is trapped in a defensive state. When our amygdala, the brain's fear processing center, perceives a partner as a threat, our survival instincts take over, shutting down the very connection we crave. Enter ketamine-assisted psychotherapy (KAP) in the relational space—a "benevolent disruptor" that biochemically dampens the amygdala, reducing fear and softening the sharp edges of human interaction. This episode unpacks a groundbreaking qualitative study profiling nine therapists who are integrating ketamine into their work with dyads, revealing diverse, highly structured approaches tailored to specific relational challenges. Whether it's a psycholytic (medium) dose to facilitate unarmored communication in Imago Relationship Therapy, a psychedelic (macro) dose to provide radical perspective shifts in Integrative Behavioral Couple Therapy, or even staggered dosing in Emotionally Focused Couple Therapy to choreograph vulnerability and receptivity, ketamine acts as a catalyst for deeply meaningful encounters. For some, the Internal Family Systems (IFS) approach even involves only one partner taking a psychedelic dose, creating a "Golden Hour" of pure, undefended self-expression that can trigger "contagious empathy" in the sober partner. Crucially, the medicine is not a magic cure. It's a temporary window of opportunity. The lasting work happens in the meticulous preparation—where couples map out their conflict cycles and set clear intentions—and the essential integration phase, where abstract insights are transformed into practical, daily habits. While the field is nascent and requires further rigorous research, these pioneering therapists are exploring how ketamine can foster radical vulnerability and help couples redefine relationship work, moving from relentless fighting to simply learning how to put the armor down and access the deep connection that's already there. Reference: Avruch, D. O. (2026). Approaches to ketamine-assisted couple therapy. Frontiers in Psychology, 17, Article 1843151. https://doi.org/10.3389/fpsyg.2026.1843151

    24 min
  2. Ketamine and Buprenorphine

    May 30

    Ketamine and Buprenorphine

    Ketamine offers rapid relief from severe depression and suicidal ideation, but its effects are often fleeting, creating a "fade" that leaves patients vulnerable. This Stanford study, published in the *American Journal of Psychiatry* (2026), tackles this challenge by exploring a novel pharmacological strategy: using low-dose buprenorphine to extend ketamine's benefits. Researchers discovered that ketamine's magic might rely on the brain's mu-opioid receptor pathways, not just the glutamate system. Buprenorphine, a partial mu-opioid agonist, gently stimulates these pathways, acting like a "trellis" to support new neural connections formed by ketamine. This approach, tested on outpatients with severe depression and suicidal ideation, showed remarkable results. Patients receiving buprenorphine maintained a significant reduction in suicidal thoughts, while those on a placebo experienced a return of ideation. Intriguingly, buprenorphine specifically targeted suicidal ideation without significantly impacting overall depression. This suggests that these conditions may operate on distinct neurobiological circuits, challenging the conventional view that suicidal ideation is simply an extreme symptom of depression. This study provides a potentially scalable and safe therapeutic option, offering a new key to turn off the switch for patients in desperate need. Reference: Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., & Schatzberg, A. F. (2026). Low-dose buprenorphine following ketamine treatment for suicidal ideation in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *American Journal of Psychiatry*, *XX*(XX), 1–11. https://doi.org/10.1176/appi.ajp.20250840

    22 min
  3. Ketamine Therapeutic Guidelines

    May 22

    Ketamine Therapeutic Guidelines

    Ketamine therapy, a beacon of hope for treatment-resistant depression, has been gaining traction, but its off-label use has raised concerns about standardization and safety. Imagine a powerful dissociative anesthetic, originally intended for battlefield use, being administered in strip mall clinics without proper monitoring or trained psychiatric support! The risk? A destabilized patient leaving traumatized instead of healed. Enter the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3), armed with a rigorous, interdisciplinary approach using the Delphi method. This isn't your typical boardroom vote; it's an anonymous, iterative process designed to eliminate bias and ego, ensuring that guidelines reflect true expert consensus. With insights from psychiatrists, anesthesiologists, ER physicians, and psychotherapists, the new guidelines address crucial aspects like comprehensive patient evaluations, dose titration, and monitoring requirements. These guidelines aren't just about individual safety; they're a step toward standardizing the industry, paving the way for insurance coverage and broader access. But will these new rules squeeze out clinics prioritizing profit over patient well-being? And what does this mean for the future of other emerging mental health therapies waiting in the wings? Reference: Mathai, D. S., Cluck, M., Aslam, A. M., Amato, E., Azam, A., Banov, M., Barrett, K. A., Bonnett, C. J., Feifel, D., Grundmann, N., Ko, H. S., McShane, R., Prashad, S., Santini, T., Stewart, L. H., Sullivan, P., Wolfsohn, S. D., Robinson, J. O., McGuire, A. L., & McInnes, L. A. (2026). Interdisciplinary, delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3). Journal of Affective Disorders, 121970. https://doi.org/10.1016/j.jad.2026.121970

    20 min
  4. Ketamine's Hidden Interactions: A Transplant Patient's Tale

    May 14

    Ketamine's Hidden Interactions: A Transplant Patient's Tale

    This episode dives into a 2026 case report revealing a surprising drug interaction: ketamine, used for pain management, induced the liver to accelerate the breakdown of critical immunosuppressant medications in a heart transplant recipient. Transplant patients rely on a delicate balance, where drugs like tacrolimus and sirolimus prevent organ rejection. However, these drugs are metabolized by specific liver enzymes (CYP3A4), making them vulnerable to interactions. In this case, a patient receiving ketamine for post-surgical pain experienced a dramatic drop in immunosuppressant levels, placing his transplanted heart at risk. Doctors responded by drastically increasing the doses, but the drug concentrations barely budged. The ketamine was essentially "teaching" the liver to clear the drugs faster, a phenomenon known as enzyme induction. The peak effect occurred a week after ketamine was started, followed by a slow recovery over three weeks. The episode emphasizes the importance of vigilant monitoring when ketamine is used in patients on narrow therapeutic range medications, and that monitoring should continue for three weeks after ketamine is discontinued to catch any potential rebound effects. Reference: Stojanova, J., Murnion, B., Burrows, F., Carlos, L., Mizuno, T., Nadai, T., Helsby, N., Muthiah, K., & Day, R. (2026). Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *46*(e70150). https://doi.org/10.1002/phar.70150

    8 min
  5. Ketamine with Traditional Antidepressants

    May 8

    Ketamine with Traditional Antidepressants

    Imagine standing in your bathroom, staring down at your current prescription bottles, terrified that your daily SSRI or SNRI might block the effects of your upcoming ketamine treatment. In Episode 62, we tackle "The Combination Question" by breaking down a highly practical 2026 brief report from Yale by Curran, Hardy, and colleagues. Looking at real-world data from 332 patients with Treatment-Resistant Depression (TRD), researchers uncovered a "beautifully boring" but life-altering reality: there is absolutely no significant difference in ketamine's clinical success regardless of what background antidepressant class a patient is currently taking. We explore the neurobiology behind this phenomenon. Traditional oral antidepressants act like "traffic cops" trying to route signals efficiently on a broken, congested monoamine highway. Ketamine, however, bypasses that system entirely; it acts on the glutamate system to release BDNF, essentially deploying a "construction crew" to pave an entirely new, high-speed neural bypass. Because they operate on completely different biological tracks, they do not interfere with one another. This data offers massive relief. It proves patients do not have to endure agonizing, dangerous drug tapers or risk a severe depressive crash just to clear their system before starting ketamine. Psychiatry is finally moving away from the exhausting merry-go-round of drug "swapping" and entering a much more compassionate era of "layering" treatments. Reference Curran, E., Hardy, M., Katz, R., Rhee, T. G., & Wilkinson, S. T. (2026). Concurrent SSRI, SNRI, or other antidepressant use not associated with differential outcomes in ketamine or esketamine treatment. The Journal of Clinical Psychiatry, 87(2), 25br16294. https://doi.org/10.4088/JCP.25br16294

    18 min
  6. The Emotion Filter

    May 1

    The Emotion Filter

    Imagine knowing exactly what someone is feeling, but your brain forces you to second-guess yourself before you can even react. That is the reality of Treatment-Resistant Depression (TRD), which creates massive "cognitive friction" in social situations. Episode 61 breaks down a fascinating 2026 computational psychiatry study by Yoldas and colleagues that proves severe depression doesn't break your ability to read emotions—it just hits the brakes on your processing speed. Using Hierarchical Drift Diffusion Modeling (HDDM), researchers discovered that TRD patients are perfectly accurate at Facial Emotion Recognition (FER). Their delay is caused by psychomotor slowing and excessively wide "decision boundaries"—meaning their depressed brains require an abnormal amount of evidence before making a choice. The most incredible part? Within just 2 to 4 hours of a single ketamine infusion, patients became significantly faster, normalizing their decision-making speeds. The data shows that ketamine doesn't need to teach the brain to read emotions again; it simply takes the foot off the cognitive brakes. Reference: Yoldas, Z., Cantenys, W., Tronche, M., Hardy, S., Samion, L., Imbault, M., Schmidt, L., & Fossati, P. (2026). Ketamine and facial emotion recognition in treatment-resistant depression: a computational account. OSF Preprints. https://doi.org/10.31234/osf.io/7vb32_v1

    21 min
  7. Ketamine vs Colorectal Cancer

    Apr 23

    Ketamine vs Colorectal Cancer

    In Episode 60, we step outside the realms of mental health and anesthesia to explore a groundbreaking 2026 study by Korkmaz and colleagues that asks a shocking question: can ketamine fight cancer directly? We dive into an in vitro study focusing on HT-29 colorectal cancer cells, exploring the potential of repositioning this common anesthetic in the oncology world. Cancer cells are notoriously hard to kill because they deactivate apoptosis—the body's natural cellular suicide program. This study reveals that ketamine effectively flips this self-destruct switch back on, showing a marked increase in early apoptosis. It alters the delicate balance of key proteins by downregulating Bcl-2, which protects the tumor, and upregulating Bax, which tears the cancer cell apart. At the same time, ketamine acts as an anti-proliferative agent, stopping the cancer cells from aggressively multiplying. How does a dissociative anesthetic achieve this? Molecular docking simulations and gene expression profiling show that ketamine interacts with NMDA and EGFR receptors, disrupting vital signaling pathways like ERK and AKT. While these findings are currently limited to petri dishes rather than human clinical trials, they open the door to a fascinating future where the anesthetics used during tumor-removal surgeries might actively help fight the disease itself.

    19 min
  8. Ketamine, the Cognitive Enhancer

    Apr 2

    Ketamine, the Cognitive Enhancer

    For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer? We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary "construction zone"—to the structural remodeling that follows. We explore ketamine's two-phase neuroprotective mechanism: acting first as a "fire extinguisher" to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as "fertilizer" by releasing BDNF to sprout new neural bridges (synaptogenesis). While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review's single human study on Huntington's disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological "window of neuroplasticity" must be actively paired with rigorous, targeted neurorehabilitation to guide the brain's rewiring. Reference: Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249

    17 min
See All (66)

4.3
out of 5
12 Ratings

About

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. Each episode explores a recent scientific study that explores an interesting aspect of ketamine treatment, ketamine therapy, and ketamine use in mental health. The podcast has covered topics ranging from ketamine and music to ketamine's surprising help in battling some cancers. Most of the papers covered are cutting edge science so you may not want to make medical decisions from them. But, each piece of evidence, good or bad, big or small, guides us to a better understanding of this miraculous medicine. If you are interested in ketamine research because you suffer from MDD or are having thoughts of suicide, please dial 988 or visit https://988lifeline.org in the US or go to https://findahelpline.com/ to find help in your location.

Information

  • Creator
    Talking Ketamine
  • Years Active
    2024 - 2026
  • Episodes
    66
  • Rating
    Clean
  • Copyright
    © 2026 Talking Ketamine
  • Show Website
    Talking Ketamine Podcast

You Might Also Like